NYSE:EW Edwards Lifesciences (EW) Stock Forecast, Price & News $69.96 -0.15 (-0.21%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$69.12▼$70.3050-Day Range$69.46▼$92.6552-Week Range$67.13▼$94.87Volume5.23 million shsAverage Volume3.18 million shsMarket Capitalization$42.53 billionP/E Ratio30.96Dividend YieldN/APrice Target$92.30 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Edwards Lifesciences MarketRank™ ForecastAnalyst RatingHold2.44 Rating ScoreUpside/Downside31.9% Upside$92.30 Price TargetShort InterestBearish2.11% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.72Based on 23 Articles This WeekInsider TradingSelling Shares$14.30 M Sold Last QuarterProj. Earnings Growth12.94%From $2.55 to $2.88 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.88 out of 5 starsMedical Sector52nd out of 969 stocksSurgical Appliances & Supplies Industry3rd out of 21 stocks 4.2 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 9 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $92.30, Edwards Lifesciences has a forecasted upside of 31.9% from its current price of $69.96.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.11% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Edwards Lifesciences has recently increased by 18.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.6 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Edwards Lifesciences this week, compared to 7 articles on an average week.Search InterestOnly 13 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows78 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 1,014% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,301,522.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.25% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.94% in the coming year, from $2.55 to $2.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 30.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.28.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 30.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 127.67.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 3.80. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 7.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edwards Lifesciences (NYSE:EW) StockEdwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesSeptember 5, 2023 | marketbeat.comWhy Analysts Say GE's Healthcare Spinoff Has $20 Upside (EW)General Electric’s spinoff, GE HealthCare Technologies Inc., is delivering some impressive results and has growth opportunities well worth tuning in to.September 28, 2023 | benzinga.comHere's How Much $100 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth TodaySeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 27, 2023 | msn.comExclusive: Edwards Lifesciences cooperating with EU antitrust regulatorsSeptember 27, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Upgraded by Oppenheimer to "Outperform"September 26, 2023 | nasdaq.comEXCLUSIVE-Edwards Lifesciences says it's cooperating with EU antitrust regulatorsSeptember 26, 2023 | msn.comOppenheimer upgrades Edwards to outperform, citing TTVR opportunitySeptember 26, 2023 | msn.comEdwards Lifesciences Commits to Fair Competition Amid Regulatory Scrutiny, Analyst Upgrades StockSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 26, 2023 | 247wallst.comOppenheimer Upgrades Edwards LifesciencesSeptember 26, 2023 | investing.comOppenheimer sees 'exciting opportunity' for Edwards LifesciencesSeptember 26, 2023 | msn.comEdwards Lifesciences said to be the target of EU antitrust raid last weekSeptember 26, 2023 | reuters.comExclusive: Edwards Lifesciences targeted in EU antitrust raid on Sept 19 - sourcesSeptember 26, 2023 | msn.comOppenheimer Upgrades Edwards Lifesciences (EW)September 26, 2023 | finance.yahoo.comEdwards Lifesciences (EW): A Deep Dive into Its Significant UndervaluationSeptember 23, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Raised to "Buy" at StockNews.comSeptember 22, 2023 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 21, 2023 | finance.yahoo.comHere's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt ResponsiblySeptember 20, 2023 | finance.yahoo.comUnveiling Edwards Lifesciences (EW)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 20, 2023 | finance.yahoo.comEdwards Lifesciences Corp (EW): A Deep Dive into Its Financial Metrics and Competitive StrengthsSeptember 18, 2023 | markets.businessinsider.comEdwards Lifesciences (EW) Gets a Hold from Bank of America SecuritiesSeptember 17, 2023 | finance.yahoo.comIs Now An Opportune Moment To Examine Edwards Lifesciences Corporation (NYSE:EW)?September 15, 2023 | benzinga.com$1000 Invested In This Stock 15 Years Ago Would Be Worth $15,000 TodaySeptember 15, 2023 | finance.yahoo.comInsider Sell: BOBO DONALD E JR Sells 4,500 Shares of Edwards Lifesciences CorpSeptember 13, 2023 | msn.comCramer Says 'I Have No Idea What's Happening' To Once-Favored Stock Down 35% YTDSeptember 13, 2023 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Edwards Lifesciences Corporation (NYSE:EW)?September 9, 2023 | finance.yahoo.comA Look At The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)See More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Company Calendar Last Earnings7/26/2023Today9/28/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees17,300Year Founded1958Price Target and Rating Average Stock Price Forecast$92.30 High Stock Price Forecast$110.00 Low Stock Price Forecast$66.00 Forecasted Upside/Downside+32.3%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$2.26 Trailing P/E Ratio30.88 Forward P/E Ratio27.37 P/E Growth3.8Net Income$1.52 billion Net Margins24.56% Pretax Margin28.35% Return on Equity25.43% Return on Assets18.04% Debt Debt-to-Equity Ratio0.09 Current Ratio3.15 Quick Ratio2.30 Sales & Book Value Annual Sales$5.66 billion Price / Sales7.50 Cash Flow$2.71 per share Price / Cash Flow25.74 Book Value$9.39 per share Price / Book7.43Miscellaneous Outstanding Shares607,916,000Free Float600,074,000Market Cap$42.43 billion OptionableOptionable Beta1.03 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 55)CEO & Director Comp: $1.04MMr. Scott B. Ullem (Age 56)Corp. VP & CFO Comp: $1.09MMr. Larry L. Wood (Age 57)Corp. VP and Group Pres of TAVR & Surgical Structural Heart Comp: $1.1MMr. Jean-Luc Lemercier (Age 66)Corp. VP of Japan, Asia Pacific & Greater China Comp: $1.24MDr. Todd J. Brinton FACCM.D., Corp. VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVP of Investor RelationsMr. Arnold A. Pinkston (Age 64)Corp. VP & Gen. Counsel Mr. Dirksen J. LehmanCorp. VP of Public AffairsMr. Donald E. Bobo Jr. (Age 61)Corp. VP of Strategy & Corp. Devel. Ms. Christine Z. McCauley (Age 58)Corp. VP of HR More ExecutivesKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNSmith & NephewNYSE:SNNView All CompetitorsInsiders & InstitutionsBaystate Wealth Management LLCBought 2,483 shares on 9/21/2023Ownership: 0.000%Larry L WoodSold 8,660 sharesTotal: $637,635.80 ($73.63/share)Donald E Bobo JrSold 4,500 sharesTotal: $331,695.00 ($73.71/share)Catherine M SzymanSold 5,000 sharesTotal: $380,000.00 ($76.00/share)Daveen ChopraSold 8,500 sharesTotal: $646,595.00 ($76.07/share)View All Insider TransactionsView All Institutional Transactions EW Stock - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price forecast for 2023? 18 analysts have issued twelve-month price objectives for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $110.00. On average, they expect the company's stock price to reach $92.30 in the next twelve months. This suggests a possible upside of 32.3% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2023? Edwards Lifesciences' stock was trading at $74.61 at the beginning of the year. Since then, EW shares have decreased by 6.5% and is now trading at $69.79. View the best growth stocks for 2023 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a increase in short interest in September. As of September 15th, there was short interest totaling 12,700,000 shares, an increase of 18.1% from the August 31st total of 10,750,000 shares. Based on an average daily volume of 3,210,000 shares, the short-interest ratio is currently 4.0 days. Approximately 2.1% of the company's stock are sold short. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings results on Wednesday, July, 26th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.01. The medical research company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.51 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 25.43% and a net margin of 24.56%. The company's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 EPS. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS), Goldman Sachs Future Health Care Equity ETF (GDOC) and Inspire 100 ETF (BIBL). When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its third quarter 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $0.55-$0.61 for the period, compared to the consensus earnings per share estimate of $0.63. The company issued revenue guidance of $1.44 billion-$1.52 billion, compared to the consensus revenue estimate of $1.47 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). What is Edwards Lifesciences' stock symbol? Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW." Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (125.25%), BlackRock Inc. (8.36%), State Street Corp (4.45%), Capital International Investors (4.44%), Alliancebernstein L.P. (3.37%) and Bank of New York Mellon Corp (2.91%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Edwards Lifesciences' stock price today? One share of EW stock can currently be purchased for approximately $69.79. How much money does Edwards Lifesciences make? Edwards Lifesciences (NYSE:EW) has a market capitalization of $42.43 billion and generates $5.66 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.26 on an earnings per share basis. How many employees does Edwards Lifesciences have? The company employs 17,300 workers across the globe. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More How can I contact Edwards Lifesciences? Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525. This page (NYSE:EW) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.